CHM.C - Chemistree Technology


#1

Résumé:

http://chemistree.ca/

logo

STRATÉGIE CORPORATIVE DE CHEMISTREE DANS L’ÉTAT DE WASHINGTON - DÉTENIR DES ACTIFS, SOUTENIR LES PRODUCTEURS

Les restrictions en vertu de la réglementation I-502 de l’État de Washington interdisent à l’entreprise et / ou à ses ses filiales d’avoir un intérêt direct sur les revenus provenant de la production, de la transformation ou de la vente au détail de marijuana dans l’État de Washington.

Une entreprise et / ou ses filiales peuvent toutefois louer des biens et octroyer des licences pour ses marques, ses services de production et de conseil aux détenteurs de permis de marijuana agréés de l’État de Washington.

Chemistree a identifié une opportunité unique dans l’industrie de culture et de transformation du cannabis dans l’État de Washington et a signé une lettre d’intention avec des parties indépendantes pour acquérir une suite d’actifs utilisés dans la culture, la production, la distribution et l’image de marque du cannabis. les actifs utilisés dans l’exploitation de la marque Sugarleaf.

Dans un processus parallèle et sous réserve de l’acquisition de l’actif, un partenaire stratégique de Chemistree, basé à Washington, acquerra la licence de producteur / transformateur I-502 Tier 3 de Washington State n ° 423406 de Sugarleaf Farm, LLC.

La société, par l’intermédiaire de Chemistree Washington Ltd., s’attend également à ce qu’elle investisse dans l’immobilier de l’État de Washington et le développe dans le but de desservir des entreprises de production et de transformation sous licence I-502.

En plus de fournir des installations spécialisées aux producteurs et aux transformateurs I-502, la Société entend développer ses techniques de culture, ses procédures d’exploitation normalisées et ses pratiques de fabrication novatrices pour aider les titulaires de permis dans leurs activités de production et de transformation. La société est d’avis que ces services créeront des synergies et des avantages qui procureront des revenus importants et à long terme au titulaire de licence et, par le fait même, à la société.

Placement privé et acquisition de SUGARLEAF

Financement par placement privé sans courtier

Chemistree est également heureuse d’annoncer un financement sans courtiers pour lever jusqu’à 2,1 millions de dollars. L’offre sera sans intermédiaire et consistera en un maximum de six millions d’unités au prix de 0,35 $ l’unité. Chaque unité sera composée d’une action ordinaire et d’un bon de souscription d’actions ordinaires (un «bon de souscription»); chaque bon de souscription permettra à son porteur d’acquérir une action ordinaire supplémentaire au prix de 0,50 $ pour une période de 24 mois après la clôture du placement privé. Les bons de souscription sont assujettis à une disposition d’accélération selon laquelle le cours de clôture des actions ordinaires de la Société sur le CSE est supérieur à 0,60 $ par action ordinaire pendant une période de dix (10) jours de transactions consécutifs (un «événement déclencheur»), la Société peut alors émettre un avis (l '«Avis d’Accélération») aux détenteurs de bons de souscription leur notifiant que les bons de souscription doivent être exercés dans les trente (30) jours calendaires suivant la date de l’Avis d’Accélération, sinon les Warrants expireront à 16:00 heures (Heure de Vancouver) le trentième (30e) jour suivant la date de l’avis d’accélération.

Le produit net du placement privé sera ajouté au fonds de roulement général, dont certains devraient être déployés pour fermer l’acquisition d’actifs à Washington. Toutefois, la clôture du placement privé n’est pas conditionnelle à la réalisation de l’acquisition de l’actif de Washington, et la Société aura le pouvoir discrétionnaire d’utiliser le produit différemment si elle croit qu’il est dans son intérêt de le faire.

Les actifs de SUGARLEAF

Suite complète des actifs opérationnels utilisés. Coût de remplacement approximatif de plus de 1 500 000 USD

Sugarleaf - Informations Financières

2017

Production de cannabis -1,938 lb
Revenus - 1 370 000 USD
Ventes brutes 707 $ / lb
COGS 600 $ / lb

2018 estimé

Production de cannabis -2.200 lbs
Revenus - 2 200 000 USD
Ventes brutes 1 000 $ / lb
COGS 600 $ / lb

Cible 2019

Production de cannabis
Revenus - 3 500 000 $ US
Ventes brutes 900 $ / lb
COGS 600 $ / lb

Renseignements sur les installations de Sugarleaf

2018

Opération intérieure de 5 000 pieds carrés
409 lumières au total
288 lumières pour floraison

2019

Opération intérieure de 10 000 pieds carrés
5 000 pieds carrés ajoutés pour localiser les opérations de traitement
et laboratoire de test.
Production supplémentaire grâce à l’efficacité et à l’espace supplémentaire
Produits de Sugarleaf dans plus de 50 magasins de détail
Plan de marketing pour augmenter à plus de 100 magasins d’ici la fin de 2018
Objectif 2019 de plus de 200 magasins
Des lignes de produits supplémentaires et des offres élargies au sein des marques actuelles

Situation financière:

INFORMATIONS SUR LE CAPITAL-ACTIONS - DISTRIBUTION DU GROUPE

Groupe de gestion et Consultants - 65%

ÉMISSIONS ANTÉRIEURES Automne 2017 6 190 800 actions ordinaires 0,255 $ pour un montant de 1 547 700 $

Actions émises 22 289 205 entièrement diluées

En Conclusion

Deux grosse pointures se sont ralliés à cette histoire soit Justin Chorbajian propriétaire de Green Planet et Dennis Hunter propriétaire de la spectaculaire CannaCraft. Considérant que l’avenir de cette industrie se situera dans la mise en marché et l’accès aux consommateurs, Chemistree est fortement appuyé par son management.

Par ailleurs au terme de ce placement la valorisation vis à vis ses pairs est très basse ce qui donne beaucoup de jeu pour un réajustement vers le haut dans les mois à suivre.

Divulgation: Actionnaire de la compagnie et participera au Placement actuel.


#2

sont-ils clients de contact financials?


#3

#4

https://ceo.ca/@nasdaq/chemistree-closes-2559820-first-tranche-of-non-brokered

Chemistree Closes $2,559,820 First Tranche of Non-Brokered Private Placement Financing

This press release is not to be distributed to U.S. newswire services or to be disseminated in the United States.

VANCOUVER, British Columbia, June 25, 2018 (GLOBE NEWSWIRE) – Chemistree Technology Inc. (Canadian Securities Exchange: CHM) (US OTCQB: CHMJF) (the “Company” or “Chemistree”) is pleased to announce that effective June 25, 2018, it has closed the first tranche of the non-brokered private placement as announced May 11, 2018 and as amended June 22, 2018, in the amount of $2,559,820.

The first tranche was comprised of 7,313,771 units, issued at $0.35 per unit for gross proceeds of $2,559,820. Each unit consists of one common share and one common share purchase warrant; each warrant will entitle the holder to acquire one additional common share for 50 cents for a period of 24 months after closing of the private placement. The warrants are subject to an acceleration provision whereby if the closing market price of the common shares of the company on the Canadian Securities Exchange is greater than 60 cents per common share for a period of 10 consecutive trading days, then the company may deliver a notice to the holders of warrants notifying the holders that the warrants must be exercised within 30 calendar days from the date of the acceleration notice, otherwise the warrants will expire at 4 p.m. PT on the 30th calendar day after the date of the acceleration notice.

The Company also issued 438,464 Finder’s Warrants in connection with the placement and the warrants will have the same terms as the common share purchase warrants included in the placement units. Securities issued under the placement are subject to a four-month hold period, which will expire four months from the date of closing.

Immediately following this private placement issuance, the Company has 28,652,976 common shares issued and outstanding.

The net proceeds of the private placement will be added to general working capital, some of which are expected to be deployed to close the Washington asset acquisition. However, the closing of the private placement is not conditional upon the completion of the Washington asset acquisition, and the Company will have discretion to use the proceeds differently if it believes it is in its best interests to do so.

The units, common shares and Warrants have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any U.S. state securities laws and may not be offered or sold in the United States absent registration or an available exemption from the registration requirement of the U.S. Securities Act and applicable U.S. state securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the units, common shares or Warrants, in any jurisdiction in which such offer, solicitation or sale would be unlawful.

The Company wishes to inform shareholders that there are significant legal restrictions and regulations that govern the cannabis industry in both Canada and the United States.

Cannabis-related Practices or Activities are Illegal Under U.S. Federal Laws

The concepts of “medical cannabis” and “recreational cannabis” do not exist under U.S. federal law. The Federal Controlled Substances Act classifies “marihuana” as a Schedule I drug. Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of safety for the use of the drug under medical supervision. As such, cannabis related practices or activities, including without limitation, the manufacture, importation, possession, use or distribution of cannabis are illegal under U.S. federal law. Strict compliance with state laws with respect to cannabis will neither absolve the Company of liability under U.S. federal law, nor will it provide a defense to any federal proceeding which may be brought against the Company. Enforcement of U.S. federal laws will be a significant risk to the business of the Company following the completion of the acquisitions, and any such proceedings brought against the Company may adversely affect the Company’s operations and financial performance.

Further information regarding the legal status of cannabis related activities and associated risk factors, including, but not limited to, risk of enforcement actions, risks that third party service providers, such as banking or financial institutions cease providing services to the Company, and the risk that Company may not be able to distribute profits, if any, from U.S. operations up to the Company, will be included in the Form 2A listing statement to be filed with the CSE.

For more information, please contact Paul Searle at (778) 240-7724 or by email at paul@chemistree.ca.

“Karl Kottmeier”
President

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the
policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of
this news release.

Information set forth in this news release may involve forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, “budget”, “scheduled” and “intend”, statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, or other similar expressions. All statements, other than statements of historical fact, included herein including, without limitation, statements about adding clients, building on the Company’s initial product offerings, entry into of definitive agreements for the asset acquisition, the timing and completion of the asset acquisition, receipt of shareholder, regulatory and CSE approvals for the asset acquisition and change of business, and the size and completion of the non-brokered private placement and the use of proceeds therefrom. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the risks identified in the Company’s reports and filings with the applicable Canadian securities regulators, that the Company may not complete the asset acquisition, failure to obtain CSE, shareholder or regulatory approvals for the asset acquisition, the Strategic Partner may fail to obtain WSLCB approval when expected or at all or may fail to acquire the Sugarleaf License on the terms and timing expected or at all, the Company may fail to enter into agreements with the Strategic Partner on the terms and timing and for the services expected or at all and changes to U.S. federal law or Washington State law or enforcement practices relating to cannabis. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made and the respective companies undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law.


#5

Chemistree Increases Private Placement Financing a Second Time

-closes Washington State acquisition
-engages investor relations teams
-stock options granted

This press release is not to be distributed to U.S. newswire services or to be disseminated in the United States.

VANCOUVER, British Columbia, July 10, 2018 (GLOBE NEWSWIRE) – Chemistree Technology Inc. (Canadian Securities Exchange:CHM) (US OTCQB:CHMJF) (the “Company” or “Chemistree”) announced that in conjunction with the final closing of the private placement announced May 11 and June 22, 2018, it has again increased the size of its non-brokered private placement. Chemistree now plans to increase the size of the placement via the issuance of up to an aggregate of thirteen million units at a price of $0.35 per unit, for gross proceeds of up to $4,550,000. Each unit will be comprised of one common share and one common share purchase warrant (a “Warrant”); each Warrant will entitle the holder to acquire one additional common share for $0.50 for a period of 24-months after closing of the private placement. The Warrants are subject to an acceleration provision whereby if the closing market price of the Common Shares of the Company on the Canadian Securities Exchange (the “Exchange”) is greater than $0.60 per Common Share for a period of ten (10) consecutive trading days (a “Trigger Event”), then the Company may deliver a notice (the “Acceleration Notice”) to the holders of Warrants notifying the holders that the Warrants must be exercised within thirty (30) calendar days from the date of the Acceleration Notice, otherwise the Warrants will expire at 4:00 p.m. (Vancouver time) on the thirtieth (30th) calendar day after the date of the Acceleration Notice.

The Company plans to close the second and final tranche of the placement tomorrow.

The net proceeds of the private placement will be added to general working capital. Closing of the private placement is subject to receipt of all necessary approvals and definitive subscriptions. All units, common shares and Warrants issued under the private placement will be subject to a four-month hold period from the closing date, in accordance with applicable Canadian securities laws.

The units, common shares and Warrants have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any U.S. state securities laws and may not be offered or sold in the United States absent registration or an available exemption from the registration requirement of the U.S. Securities Act and applicable U.S. state securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the units, common shares or Warrants, in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Washington Acquisition
Further to the definitive asset purchase agreement announced on June 1, 2018, the Company has completed, through its wholly owned subsidiary, Chemistree Washington Ltd. (“Chemistree Washington”), the purchase of a suite of Washington-based assets used in cannabis cultivation, production, distribution and branding.

Chemistree Washington entered into a definitive asset purchase agreement with Elite Holdings Inc. with respect to the Washington acquisition. Pursuant to the Washington acquisition agreement, Chemistree Washington acquired certain assets, including, but not limited to, all inventory, leases, software, furniture, systems, equipment and lighting from the Washington vendor. The acquisition does not include any receivables, payables, warranties, employee or tax liabilities of the Washington vendor.

Investor Relations Arrangements
Chemistree is also pleased to announce that it has entered into consulting agreements with Contact Financial Corp. and Adelaide Capital Markets Inc. (“IR Firms”) to provide investor relations and communication services. The Company has selected the IR Firms as experienced arm’s length firms that specialize in small-cap growth companies and will generate value by sharing Chemistree’s compelling story to wealth managers, brokers, institutions, analysts, portfolio managers, retail and high net worth clients globally. Contact Financial, headed by Kirk Gamley, is based in Vancouver, British Columbia, and Adelaide Capital, Markets headed by Deborah Honig and Jackie Kelly, is based in Toronto, Ontario.

In addition to the contracted compensation, and subject to Exchange approval, Chemistree has agreed to grant Contact Financial and Adelaide Capital Markets options to acquire 150,000 and 100,000 common shares, respectively, in the capital of the Company at a price of $0.41 per share that vest quarterly over twelve months and have a five-year term.

Other than 1,400,000 common shares and 200,000 warrants held directly and indirectly by Contact Financial, none of Contact Financial, Adelaide Capital Markets or their respective owners has any interest, directly or indirectly, in the Company or its securities, or any right or intent to acquire such an interest, other than the above stock option grants.

Option Grant
Pursuant to the Company’s stock option plan, the Company has granted options to purchase 250,000 common shares at $0.41 per share to certain eligible officers and consultants. The options expire in five years.

The Company wishes to inform shareholders that there are significant legal restrictions and regulations that govern the cannabis industry in both Canada and the United States.

Cannabis-related Practices or Activities are Illegal Under U.S. Federal Laws.

The concepts of “medical cannabis” and “recreational cannabis” do not exist under U.S. federal law. The Federal Controlled Substances Act classifies “marihuana” as a Schedule I drug. Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of safety for the use of the drug under medical supervision. As such, cannabis related practices or activities, including without limitation, the manufacture, importation, possession, use or distribution of cannabis are illegal under U.S. federal law. Strict compliance with state laws with respect to cannabis will neither absolve the Company of liability under U.S. federal law, nor will it provide a defense to any federal proceeding which may be brought against the Company. Enforcement of U.S. federal laws will be a significant risk to the business of the Company following the completion of the acquisitions, and any such proceedings brought against the Company may adversely affect the Company’s operations and financial performance.

Further information regarding the legal status of cannabis related activities and associated risk factors, including, but not limited to, risk of enforcement actions, risks that third party service providers, such as banking or financial institutions cease providing services to the Company, and the risk that Company may not be able to distribute profits, if any, from U.S. operations up to the Company, will be included in the Form 2A listing statement to be filed with the CSE.

“Karl Kottmeier”
President

For further information please contact:
Chemistree Technology Inc.
Karl Kottmeier, President
Phone: 604-678-8941
Email: info@chemistree.ca
Suite 810 – 609 Granville Street
Vancouver, BC V7Y 1G5

For investor relations please contact:
Contact Financial Corp.
Rob Gamley
Phone: 604-689-7422
Email: rob@contactfinancial.com

Adelaide Capital Markets Inc.
Jackie Kelly
Phone: 416-301-2949
Email: jackie@adelaidecapital.ca

Chemistree Completes Final Tranche of Private Placement Financing

Chemistree Completes Final Tranche of Private Placement Financing

VANCOUVER, British Columbia, July 12, 2018 (GLOBE NEWSWIRE) – Chemistree Technology Inc. (Canadian Securities Exchange:CHM) (US OTCQB:CHMJF) (the “Company” or “Chemistree”) is pleased to announce that effective July 11, 2018, it has closed the final tranche of the non-brokered private placement as announced May 11, and as amended June 22, and July 10, 2018, for gross proceeds of $1,949,365. Gross proceeds from the two closings aggregate $4,509,184, which has been added to general working capital.

The July 11, 2018, final tranche was comprised of 5,569,613 units, issued at $0.35 per unit. Each unit consists of one common share and one common share purchase warrant; each warrant will entitle the holder to acquire one additional common share for $0.50 cents for a period of 24 months after closing of the private placement. The warrants are subject to an acceleration provision whereby if the closing market price of the common shares of the Company on the Canadian Securities Exchange (the “CSE”) is greater than $0.60 per common share for a period of 10 consecutive trading days, then the Company may deliver a notice to the holders of warrants notifying the holders that the warrants must be exercised within 30 calendar days from the date of the acceleration notice, otherwise the warrants will expire at 4:00 p.m. PT on the 30th calendar day after the date of the acceleration notice.

The Company also issued 257,748 Finder’s Warrants in connection with the final tranche, and the warrants will have the same terms as the common share purchase warrants included in the placement units. Securities issued under the placement are subject to a four-month hold period, which will expire four months from the date of closing. Immediately following this private placement issuance, the Company has 34,222,589 common shares issued and outstanding.

The units, common shares and Warrants have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any U.S. state securities laws and may not be offered or sold in the United States absent registration or an available exemption from the registration requirement of the U.S. Securities Act and applicable U.S. state securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the units, common shares or Warrants, in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Change of Business Filing
On June 27, 2018, Chemistree received conditional approval from the CSE for its change of business from a Technology Issuer to an Investment Issuer, which was deemed a fundamental change under CSE Policy 8. With the completion of the private placement financing, the Company has met all the conditions set-out by the CSE. In due course following submission and acceptance of the final documentation required by the CSE, the Company expects that the CSE will reinstate trading in the Company’s common shares. Following final approval by the CSE, the Company expects to issue a further news release announcing final approval by the CSE and the reinstatement of trading.

About Chemistree Technology Inc.
Chemistree Technology Inc. is an investment company dedicated to the U.S. cannabis sector, providing turn key solutions for the U.S. regulated cannabis industry. The Company’s corporate strategy is to acquire and develop vertically integrated U.S. cannabis assets, leveraging management’s decades of expertise in the cannabis industry and corporate finance to own and operate licensed cultivation, processing, distribution and retail facilities throughout the U.S. The Company currently owns assets in Washington State used to operate the Sugarleaf brand and has a robust pipeline of assets to grow its base of business across the U.S. For more information, visit www.chemistree.ca.

Advisory
The Company wishes to inform shareholders that there are significant legal restrictions and regulations that govern the cannabis industry in both Canada and the United States.

Cannabis-related Practices or Activities are Illegal Under U.S. Federal Laws

The concepts of “medical cannabis” and “recreational cannabis” do not exist under U.S. federal law. The Federal Controlled Substances Act classifies “marihuana” as a Schedule I drug. Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of safety for the use of the drug under medical supervision. As such, cannabis related practices or activities, including without limitation, the manufacture, importation, possession, use or distribution of cannabis are illegal under U.S. federal law. Strict compliance with state laws with respect to cannabis will neither absolve the Company of liability under U.S. federal law, nor will it provide a defense to any federal proceeding which may be brought against the Company. Enforcement of U.S. federal laws will be a significant risk to the business of the Company following the completion of the acquisitions, and any such proceedings brought against the Company may adversely affect the Company’s operations and financial performance.

Further information regarding the legal status of cannabis related activities and associated risk factors, including, but not limited to, risk of enforcement actions, risks that third party service providers, such as banking or financial institutions cease providing services to the Company, and the risk that Company may not be able to distribute profits, if any, from U.S. operations up to the Company, will be included in the Form 2A listing statement to be filed with the CSE.

“Karl Kottmeier”
President

For further information please contact:
Chemistree Technology Inc.
Karl Kottmeier, President
Phone: 604-678-8941
Email: info@chemistree.ca

For investor relations please contact:
Contact Financial Corp.
Rob Gamley
Phone: 604-689-7422
Email: rob@contactfinancial.com Adelaide Capital Markets Inc.
Jackie Kelly
Phone: 416-301-2949
Email: jackie@adelaidecapital.ca


#6

Once-Iffy U.S.-Focused Pot Stocks Are Becoming Investor Darlings

Les élection mid-term aux USA vont jouer un rôle clef dans la légalisation au niveau Fédéral. Il faut être positionner sur cette opportunité qui sera 100 fois plus importante que ce qu’on a pu observer ici au Canada.


#7

CHEMISTREE ANNOUNCES FORMAL CLOSING OF CALIFORNIA LAND PURCHASE

ANCOUVER, British Columbia, Aug. 09, 2018 (GLOBE NEWSWIRE) – Chemistree Technology Inc. (Canadian Securities Exchange: CHM) (US OTCQB: CHMJF) (the “Company” or “Chemistree”) is pleased to announce that the Company has now closed the previously announced transaction to purchase 9.55 acres of bare land located within the Desert Hot Springs, California “Light Industrial Lands Designated for Marijuana Cultivation” area.

Chemistree, through its indirect, wholly-owned California subsidiary CHM Desert LLC, has received final notification that title to the DHS property has been transferred and escrow has now closed on the purchase contract with an arm’s length vendor for the purchase of 9.55 acres of fee simple, vacant land in the City of Desert Hot Springs, Riverside County, California (the “DHS property”). Consideration for the purchase was $1,233,800 USD.

The DHS property can support development plans and a Conditional Use Permit application for a total of three (3) 68,000 sq. ft cultivation and processing buildings on the site totaling approximately 205,000 sq. ft., together with the required ancillary space for parking, firefighting equipment and site security, based on the regulations of the City of Desert Hot Springs.

About Chemistree Technology Inc.
Chemistree Technology Inc. is an investment company dedicated to the U.S. cannabis sector, providing turn key solutions for the U.S. regulated cannabis industry. The Company’s corporate strategy is to acquire and develop vertically integrated U.S. cannabis assets, leveraging management’s decades of expertise in the cannabis industry and corporate finance to own and operate licensed cultivation, processing, distribution and retail facilities throughout the U.S. The Company currently owns assets in Washington State used to operate the Sugarleaf brand, prospective cannabis cultivation lands in California, and has a robust pipeline of assets to grow its base of business across the U.S. For more information, visit www.chemistree.ca.

Advisory
The Company wishes to inform shareholders that there are significant legal restrictions and regulations that govern the cannabis industry in both Canada and the United States.

Cannabis-related Practices or Activities are Illegal Under U.S. Federal Laws

The concepts of “medical cannabis” and “recreational cannabis” do not exist under U.S. federal law. The Federal Controlled Substances Act classifies “marihuana” as a Schedule I drug. Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of safety for the use of the drug under medical supervision. As such, cannabis related practices or activities, including without limitation, the manufacture, importation, possession, use or distribution of cannabis are illegal under U.S. federal law. Strict compliance with state laws with respect to cannabis will neither absolve the Company of liability under U.S. federal law, nor will it provide a defense to any federal proceeding which may be brought against the Company. Enforcement of U.S. federal laws will be a significant risk to the business of the Company following the completion of the acquisitions, and any such proceedings brought against the Company may adversely affect the Company’s operations and financial performance.

Further information regarding the legal status of cannabis related activities and associated risk factors, including, but not limited to, risk of enforcement actions, risks that third-party service providers, such as banking or financial institutions cease providing services to the Company, and the risk that Company may not be able to distribute profits, if any, from U.S. operations up to the Company, are included in the Form 2A listing statement filed with the CSE.

“Karl Kottmeier”
President

For further information please contact:
Chemistree Technology Inc.
Karl Kottmeier, President
Phone: 604-678-8941
Email: info@chemistree.ca

For investor relations please contact:
Contact Financial Corp.
Rob Gamley
Phone: 604-689-7422
Email: rob@contactfinancial.com Adelaide Capital Markets Inc.
Jackie Kelly
Phone: 416-301-2949
Email: jackie@adelaidecapital.ca


#8

Chemistree Announces Strategic Investment in Pasha Brands

VANCOUVER, British Columbia, Oct. 04, 2018 (GLOBE NEWSWIRE) – Chemistree Technology Inc. (Canadian Securities Exchange: CHM) (US OTCQB: CHMJF) (the “Company” or “Chemistree”) is pleased to announce that the Company has made a strategic investment in Pasha Brands, via their current equity capital financing.

Pasha is a west coast company firmly established in B.C’s craft cannabis industry and all of the related brands that have given the region its international reputation as the center of the cannabis world. Pasha is a vertically integrated cannabis brand company with several internationally recognized brands, a proven history in cannabis retailing, and with its final stage LP applicant, BC Craft Supply Co., Pasha will own and operate a Health Canada approved Licensed Processing facility on Vancouver Island, where it will assist in licensing select craft growers and making world famous BC Bud available coast to coast. BC Craft Supply Co. will be Canada’s most productive LP, without growing a single gram.

Chemistree president Karl Kottmeier commented, “We are excited to support Pasha and begin what we believe will be a successful relationship with the company. We see a future where Pasha represents the brands Chemistree develops in California and Washington, including our partner brand Sugarleaf.”

The investment in Pasha amounts to less than 10% of both Chemistree’s working capital and the current Pasha financing.

About Chemistree Technology Inc.
Chemistree Technology Inc. is an investment company dedicated to the U.S. and international cannabis sector, providing turn key solutions for the regulated cannabis industry. The Company’s corporate strategy is to acquire and develop vertically integrated cannabis assets, leveraging management’s decades of expertise in the cannabis industry and corporate finance to own and operate licensed cultivation, processing, distribution and retail facilities. The Company currently owns assets in Washington State used to operate the Sugarleaf brand, prospective cannabis cultivation lands in California, a first investment in the Canadian cannabis sector through Pasha Brands and has a robust pipeline of assets to grow its base of business. For more information, visit www.chemistree.ca.

Advisory
The Company wishes to inform shareholders that there are significant legal restrictions and regulations that govern the cannabis industry in both Canada and the United States.

Cannabis-related Practices or Activities are Illegal Under U.S. Federal Laws

The concepts of “medical cannabis” and “recreational cannabis” do not exist under U.S. federal law. The Federal Controlled Substances Act classifies “marihuana” as a Schedule I drug. Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of safety for the use of the drug under medical supervision. As such, cannabis related practices or activities, including without limitation, the manufacture, importation, possession, use or distribution of cannabis are illegal under U.S. federal law. Strict compliance with state laws with respect to cannabis will neither absolve the Company of liability under U.S. federal law, nor will it provide a defense to any federal proceeding which may be brought against the Company. Enforcement of U.S. federal laws will be a significant risk to the business of the Company following the completion of the acquisitions, and any such proceedings brought against the Company may adversely affect the Company’s operations and financial performance.

Further information regarding the legal status of cannabis related activities and associated risk factors, including, but not limited to, risk of enforcement actions, risks that third-party service providers, such as banking or financial institutions cease providing services to the Company, and the risk that Company may not be able to distribute profits, if any, from U.S. operations up to the Company, are included in the Form 2A listing statement filed with the CSE.

“Karl Kottmeier”
President

For further information please contact:
Chemistree Technology Inc.

Karl Kottmeier, President
Phone: 604-678-8941
Email: info@chemistree.ca||
|||
|For investor relations please contact:||
|Contact Financial Corp.
Frederick Chabot
Phone: 438-863-7071
Email: frederick@contactfinancial.com|Adelaide Capital Markets Inc.
Jackie Kelly
Phone: 416-301-2949
Email: jackie@adelaidecapital.ca|


#9

PashaDeck[1]-min.pdf (2,2 Mo)

La Présentation de Pasha Brands

Pasha is a vertically integrated cannabis brand company with a
proven history in cannabis retailing, operating licensed stores throughout British Columbia.

Pasha owns and operates BC’s largest chain of licensed cannabis retail outlets operating
throughout Vancouver and will expand its reached into new municipalities in 2018. Pasha owns
Edo, a creative cannabis edibles company. With late stage LP applicant Royal Green Acres Ltd.,
Pasha will own and operate a Health Canada approved Licensed Production & Processing facility in
Nanaimo, BC, where it will assist in licensing select craft growers and making world famous BC Bud
available to the world.

Pasha will be Canada’s most productive licensed producer, without growing a single gram.


#10

Sheldon Aberman Joins Chemistree Board of Directors

Sheldon est la Clef de Voûte de toute cette histoire. Si j’avais une compagnie modèle pour CHM ce serait CRZ CannaRoyalty.

Dear Canada: This is what marijuana legalization looks like in California


#11

Succeeding in California cannabis: four questions with Chemistree Technologies president Karl Kottmeier


#12

Trace écrite